1-5 of 5
Ram Kumar Singh
Close
Sort by
Journal Articles

Iberdomide Enhances Dara Mediated Cytotoxicity through Upregulation of CDC Activity and Elevated NK Cell Mediated ADCC

Peilin Ma, Vinidhra Sridharan, Krista Wollerman, Debjani Dutta, Ram Kumar Singh, Sambuddo Mukherjee, Chad C. Bjorklund, Patrick R Hagner, Michael Amatangelo, Anita K. Gandhi
Journal: Blood
Blood (2023) 142 (Supplement 1): 3289.
https://doi.org/10.1182/blood-2023-189423
Published: 2023
Journal Articles

The Anti-B-Cell Maturation Antigen (BCMA) Antibody-α-Amanitin Conjugate Hdp-101 Induces Immunogenic Cell Death and Immunologic Memory in Models of Multiple Myeloma

Ram Kumar Singh, PhD, Richard J. Jones, PhD, Fazal M. Shirazi, PhD, Jianxuan M. Zou, PhD, Hua Wang, PhD, Hans C. Lee, MD, Elisabet E. Manasanch, MD, Isere Kuiatse, PhD, Andreas Pahl, PhD, Robert Z. Orlowski, MDPhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 9–10.
https://doi.org/10.1182/blood-2020-141615
Published: 2020
Journal Articles

Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma

Junling Zhuang, Fazal Shirazi, Ram Kumar Singh, Isere Kuiatse, Hua Wang, Hans C. Lee, Zuzana Berkova, Allison Berger, Marc Hyer, Nibedita Chattopadhyay, Sakeena Syed, Judy Qiuju Shi, Jie Yu, Vaishali Shinde, Stephen Tirrell, Richard Julian Jones, Zhiqiang Wang, R. Eric Davis, Robert Z. Orlowski
Journal: Blood
Blood (2019) 133 (14): 1572–1584.
https://doi.org/10.1182/blood-2018-06-859686
Published: 2019
Includes: Supplemental data
Journal Articles

Activating KRAS , NRAS , and BRAF Mutants Enhance Proteasome Capacity and Reduce Endoplasmic Reticulum Stress in Multiple Myeloma, Thereby Promoting Plasma Cell Survival and Proteasome Inhibitor Resistance

Fazal Shirazi, PhD, Richard J. Jones, PhD, Isere Kuiatse, PhD, Zuzana Berkova, PhD, Hua Wang, PhD, Hans C. Lee, MD, Samuel Hong, PhD, Ram Kumar Singh, PhD, Lawrence Robert Dick, PhD, Nibedita Chattopadhyay, PhD, Robert Z. Orlowski, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 406.
https://doi.org/10.1182/blood-2018-99-117577
Published: 2018
Journal Articles

HDP101, a Novel B-Cell Maturation Antigen (BCMA)-Targeted Antibody Conjugated to α-Amanitin, Is Active Against Myeloma with Preferential Efficacy Against Pre-Clinical Models of Deletion 17p

Ram Kumar Singh, PhD, Richard J. Jones, PhD, Samuel Hong, PhD, Fazal Shirazi, PhD, Hua Wang, PhD, Isere Kuiatse, PhD, Andreas Pahl, Robert Z. Orlowski, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 593.
https://doi.org/10.1182/blood-2018-99-118412
Published: 2018